Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBIT: 2017-2025

Historic EBIT for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$40.3 million.

  • Dianthus Therapeutics' EBIT fell 34.74% to -$40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.3 million, marking a year-over-year decrease of 69.24%. This contributed to the annual value of -$101.9 million for FY2024, which is 111.45% down from last year.
  • As of Q3 2025, Dianthus Therapeutics' EBIT stood at -$40.3 million, which was down 15.35% from -$34.9 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' EBIT peaked at -$7.7 million during Q1 2023, and registered a low of -$40.3 million during Q3 2025.
  • Over the past 3 years, Dianthus Therapeutics' median EBIT value was -$22.2 million (recorded in 2024), while the average stood at -$23.5 million.
  • Data for Dianthus Therapeutics' EBIT shows a maximum YoY crashed of 146.34% (in 2024) over the last 5 years.
  • Over the past 4 years, Dianthus Therapeutics' EBIT (Quarterly) stood at -$10.7 million in 2022, then declined by 21.16% to -$13.0 million in 2023, then tumbled by 146.34% to -$31.9 million in 2024, then tumbled by 34.74% to -$40.3 million in 2025.
  • Its last three reported values are -$40.3 million in Q3 2025, -$34.9 million for Q2 2025, and -$33.2 million during Q1 2025.